NCT01209299View on ClinicalTrials.gov

Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

January 19, 2012

Primary Completion Date

February 19, 2012

Study Completion Date

February 19, 2012

Conditions
Melanoma (Skin)
Interventions
GENETIC

DNA methylation analysis

GENETIC

gene expression analysis

OTHER

laboratory biomarker analysis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

ECOG-ACRIN Cancer Research Group

NETWORK

NCT01209299 - Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate | Biotech Hunter | Biotech Hunter